Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Gene Therapy with LentiGlobin BB305 in Sickle Cell Disease
2019-000331-63Phase 3Terminated
- Sponsor
- bluebird bio, Inc.
- Start
- Jul 2020
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of betibeglogene autotemcel in sickle cell disease (SCD), sponsored by bluebird bio, Inc. Primary endpoint: Globin Response. Started Jul 2020; status: terminated.
02
Drugs
betibeglogene autotemcel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2019-000331-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000331-63.